Iterum Therapeutics PLC
ITRM0.370USD
-0.011-2.86%
收盘 12/19, 16:00（美东）报价延迟15分钟
18.13M总市值
亏损市盈率 TTM
关于 Iterum Therapeutics PLC 公司
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Iterum Therapeutics PLC简介
公司代码ITRM
公司名称Iterum Therapeutics PLC
上市日期May 25, 2018
CEOFishman (Corey N)
员工数量9
证券类型Ordinary Share
年结日May 25
公司地址3 Dublin Landings
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Ireland
邮编D01 C4E0
电话35319038354
网址https://www.iterumtx.com/
公司代码ITRM
上市日期May 25, 2018
CEOFishman (Corey N)
Iterum Therapeutics PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+2.55%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Christine Coyne
Ms. Christine Coyne
Chief Commercial Officer
Chief Commercial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+2.55%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Squarepoint Capital LLP
0.84%
Apollon Financial LLC
0.47%
Dunne (Michael W)
0.46%
OneDigital Investment Advisors LLC
0.36%
Fishman (Corey N)
0.26%
其他
97.61%
持股股东
持股股东
占比
Squarepoint Capital LLP
0.84%
Apollon Financial LLC
0.47%
Dunne (Michael W)
0.46%
OneDigital Investment Advisors LLC
0.36%
Fishman (Corey N)
0.26%
其他
97.61%
股东类型
持股股东
占比
Investment Advisor
1.38%
Investment Advisor/Hedge Fund
0.86%
Individual Investor
0.79%
Hedge Fund
0.15%
Research Firm
0.15%
Bank and Trust
0.01%
其他
96.65%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
51
2.44M
5.09%
-582.93K
2025Q2
52
1.58M
3.92%
-2.61M
2025Q1
55
1.53M
3.82%
-2.58M
2024Q4
58
1.64M
5.63%
-1.56M
2024Q3
56
2.45M
10.80%
+569.01K
2024Q2
63
660.22K
3.99%
-1.18M
2024Q1
68
1.18M
7.18%
-978.56K
2023Q4
68
641.88K
4.78%
-516.61K
2023Q3
72
394.43K
3.03%
-679.64K
2023Q2
77
605.90K
4.67%
-186.78K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Squarepoint Capital LLP
456.86K
1.02%
+456.86K
--
Jun 30, 2025
Apollon Financial LLC
250.25K
0.56%
--
--
Jun 30, 2025
Dunne (Michael W)
235.00K
0.53%
+15.00K
+6.82%
Aug 08, 2025
OneDigital Investment Advisors LLC
161.00K
0.36%
+60.00K
+59.41%
Jun 30, 2025
Fishman (Corey N)
137.06K
0.31%
--
--
Jul 01, 2025
CAPTRUST Financial Advisors
11.50K
0.03%
+11.50K
--
Jun 30, 2025
Renaissance Technologies LLC
471.90K
1.06%
+231.00K
+95.89%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
公告日期
类型
比率
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
常见问题
Iterum Therapeutics PLC的前五大股东是谁？
Iterum Therapeutics PLC 的前五大股东如下：
Squarepoint Capital LLP持有股份：456.86K，占总股份比例：1.02%。
Apollon Financial LLC持有股份：250.25K，占总股份比例：0.56%。
Dunne (Michael W)持有股份：235.00K，占总股份比例：0.53%。
OneDigital Investment Advisors LLC持有股份：161.00K，占总股份比例：0.36%。
Fishman (Corey N)持有股份：137.06K，占总股份比例：0.31%。
Squarepoint Capital LLP持有股份：456.86K，占总股份比例：1.02%。
Apollon Financial LLC持有股份：250.25K，占总股份比例：0.56%。
Dunne (Michael W)持有股份：235.00K，占总股份比例：0.53%。
OneDigital Investment Advisors LLC持有股份：161.00K，占总股份比例：0.36%。
Fishman (Corey N)持有股份：137.06K，占总股份比例：0.31%。
Iterum Therapeutics PLC的前三大股东类型是什么？
Iterum Therapeutics PLC 的前三大股东类型分别是：
Squarepoint Capital LLP
Apollon Financial LLC
Dunne (Michael W)
Squarepoint Capital LLP
Apollon Financial LLC
Dunne (Michael W)
有多少机构持有Iterum Therapeutics PLC(ITRM)的股份？
截至2025Q3，共有51家机构持有Iterum Therapeutics PLC的股份，合计持有的股份价值约为2.44M，占公司总股份的5.09%。与2025Q2相比，机构持股有所增加，增幅为1.17%。
哪个业务部门对Iterum Therapeutics PLC的收入贡献最大？
在--，--业务部门对Iterum Therapeutics PLC的收入贡献最大，创收--，占总收入的--%。
